Effect of methyleugenol on expression of MUC5AC in nasal mucosa of rats with allergic rhinitis.
- Author:
Nannan MENG
1
;
Yun HOU
2
;
Yan GUI
2
;
Kehu XI
2
;
Youhu WANG
2
;
Jing YANG
2
;
Hong CHEN
3
;
Xiaobing ZHANG
4
Author Information
1. Department of Child Care, the First Hospital of Lanzhou University, Lanzhou 730000, China.
2. Department of Otolaryngology-Head and Neck Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
3. Department of Child Care, the First Hospital of Lanzhou University, Lanzhou 730000, China. CH701@163.com.
4. Department of Otolaryngology-Head and Neck Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China. 790736924@qq.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Dose-Response Relationship, Drug;
Down-Regulation;
drug effects;
Eugenol;
analogs & derivatives;
pharmacology;
Loratadine;
Mucin 5AC;
drug effects;
physiology;
Nasal Mucosa;
chemistry;
Ovalbumin;
Rats;
Rats, Sprague-Dawley;
Rats, Wistar;
Rhinitis, Allergic;
chemically induced;
drug therapy;
physiopathology
- From:
Journal of Zhejiang University. Medical sciences
2016;45(5):477-485
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the effect of methyleugenol on expression of MUC5AC in nasal mucosa of rats with allergic rhinitis (AR).Seventy-two Wistar rats were randomly divided into 6 groups:normal control group, AR group, loratadine group, low-dose methyleugenol group, middle-dose methyleugenol group and high-dose methyleugenol group with 12 rats in each group. AR was induced by intraperitoneal injection of ovalbumin in latter 5 groups. 10 mg loratadine q.d was given to rats in loratadine group by gavage; and 10 mg/kg, 20 mg/kg and 40 mg/kg methyleugenol were given by gavege q.d to rats in low-, middle-and high-dose methyleugenol groups, respectively. Nasal mucosa samples were obtained from rats at 1, 2, 4 and 6 weeks after drug intervention. The expression of MUC5AC protein and mRNA in nasal mucosa was detected by immunohistochemistry and real-time fluorescence quota PCR (RT-PCR), respectively.Compared with AR, the percentage of cells staining positively for MUC5AC protein and the relative quantity of MUC5AC mRNA in middle-and high-dose methyleugenol groups were significantly decreased after 2 and 4 weeks of drug intervention (<0.05), but no such decrease was observed in low-dose methyleugenol group at all time points (>0.05). The percentage of cells with positive expression of MUC5AC protein and mRNA in loratadine group were significantly decreased after 1 week of administration (<0.05). The percentage of cells with positive MUC5AC protein in middle-dose methyleugenol group was higher than that in loratadine group (<0.05) after 6 week of drug intervention, but the difference was not seen in high-dose group (>0.05). There was no significant difference in relative quantities of MUC5AC mRNA after 4 weeks of administration between high-and middle-dose methyeugenol groups and loratadine group (>0.05).Methyleugenol can attenuate AR through inhibiting the expression of MUC5AC mRNA and protein in nasal mucosa of AR rats.
